Therapeutic Drug Monitoring Market

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2027

Report Code: MD 4185 Feb, 2023, by marketsandmarkets.com

The global therapeutic drug monitoring market in terms of revenue was estimated to be worth $1.8 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027. The growth of this market is primarily driven by an amplifying focus on research experimentation associated with therapeutic drug monitoring and an increase in severe diseases. However, the requirement for massive capital investments and the hesitancy of compact hospitals to offer therapeutic drug monitoring services may restrain the growth of this market.

Attractive Opportunities in the Therapeutic Drug Monitoring Market

Therapeutic Drug Monitoring Market

To know about the assumptions considered for the study, Request for Free Sample Report

Recession Impact on the Therapeutic Drug Monitoring Market

Market growth is anticipated to slow due to concerns about a possible recession. According to an article published in the Wall Street Journal in 2022, the fear of recession has driven a 9% gain for the NYSE Arca Pharmaceutical Index over the past year and a 13.1% decline for the S&P 500. Trends are expected to be like the COVID-19 recession, wherein procedural volumes and routine testing in a particular country or region depended on the spread of COVID-19 and actions taken by regional authorities. For instance, global cardiovascular and neuromodulation procedural volumes dropped during COVID-19, directly affecting the demand for Abbott's medical devices and diagnostic tests.

  • The recession has had an impact on the quarterly revenue of companies such as Abbott Laboratories (US) and may have an impact on capital spending.
  • The primaries also confirmed the impact of the recession.
  • The company's volume analysis for 2020–2021 further aided the recession impact analysis.

Therapeutic Drug Monitoring Market Dynamics

Driver: Importance of therapeutic drug monitoring in organ transplant procedures

Conducting therapeutic drug monitoring for immunosuppressive medications is essential in managing patients undergoing solid-organ transplantation. A person receiving an organ transplant is prescribed immunosuppressants so the body does not reject the organ. When administering immunosuppressants, clinicians need to individualise a patient's drug therapy and ensure an optimal balance between therapeutic efficacy and the probability of adverse effects. Patients present different pharmacodynamics and pharmacokinetics, so achieving this goal with immunosuppressant therapy monitoring can be challenging.

Therapeutic drug monitoring is used before administering immunosuppressants as it minimises the pharmacokinetic component of variability. Improper drug concentrations in immunosuppressants can lead to adverse effects in transplant patients. Supra-therapeutic drug concentrations can put the patient at risk of over-immunosuppression, which may cause infection. On the other hand, sub-therapeutic drug concentrations can cause the recipient's body to reject an allograft. This inter-individual variability in drug concentrations creates the need for therapeutic drug monitoring.

The importance of therapeutic drug monitoring has grown due to the rising number of organ transplant procedures being performed. In 2020, 39,000 transplants will be performed in the US, and 106,771 children, women, and men are on the national transplant waiting list (source: HRSA).

Opportunity: increasing prevalence of autoimmune diseases.

Autoimmune diseases affect approximately 3% of the US population (10 million people) (Johns Hopkins University, 2022). Similarly, around 4% of the world's population is affected by one of more than 80 different autoimmune diseases. The most common autoimmune disorders include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn's disease, psoriasis, and scleroderma. It is also estimated by the American Autoimmune Related Diseases Association (AARDA) that as many as 50 million Americans are living with an autoimmune disease, at a cost of USD 86 billion a year. According to the US Department of Health and Human Services (HHS), these diseases represent the fourth-largest cause of disability among women in the US. They are the eighth-leading cause of death for women between the ages of 15 and 64. As a result, the introduction of new therapeutics for treating inflammatory autoimmune diseases has increased rapidly in the last decade. For instance, tacrolimus is a widely used immunosuppressive drug in patients with autoimmune diseases.

Challenge: Alternatives to conventional therapeutic drug monitoring

In therapeutic drug monitoring, many patients require regular blood testing to monitor their health and progress. After specific procedures, such as renal transplants, physicians must monitor the patient's condition frequently through blood analysis to help ensure consistent drug concentrations in the patient's bloodstream. Generally, therapeutic drug monitoring is challenging to maintain in this process without compromising the specimen quality and accuracy or the patient's comfort and convenience, if not both. It becomes significantly more challenging when it requires participation from children, the elderly, or those who live in rural or isolated areas.

To reduce drawbacks, dried blood spot (DBS) sampling for therapeutic drug monitoring can be an alternative to conventional blood sampling, especially in children. As per a research article, switching to DBS for therapeutic drug monitoring offered easy results and improved cost-effectiveness. For instance, for children with renal transplants treated with immunosuppressants, the total societal costs for conventional sampling were USD 287.5 (EUR 259) for one sample. In contrast, home sampling costs were $113.2 (EUR 102) for a sample.

Companies have also adopted the benefits offered by DBS to provide ease in therapeutic drug monitoring compared to the conventional method. For instance, Neoteryx, LLC, provides the Mitra Device, a single-use, non-sterile device that enables easy at-home sampling for therapeutic drug monitoring in paediatric patients.

chemiluminescence immunoassays (CLIAs) in the product's immunoassay therapeutic drug monitoring segment to witness the highest growth as well as the largest share in the therapeutic drug monitoring market during the forecast period.

The market is divided into chemiluminescence immunoassays, colorimetric immunoassays, fluorescence immunoassays, radioimmunoassays, and other immunoassays based on the immunoassay. The chemiluminescence immunoassays segment is projected to grow at the highest CAGR during the forecast period because these assays are commonly used in TDM in either enzyme-amplified or direct chemiluminescence measurements.

In 2021, the US accounted for the largest share of the North American therapeutic drug monitoring market.

Based on the region, the North American Therapeutic Drug Monitoring market is segmented into the US and Canada. In 2021, the US accounted for the largest share of the North American therapeutic drug monitoring market. Growth in this market can be attributed to rising awareness and adoption of precision medicine, the rising number of drug development activities or launches, and the well-established reimbursement framework for clinical diagnostics.

Therapeutic Drug Monitoring Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Some of the major players operating in this market are Abbott (US), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers AG. (Germany), Thermo Fisher Scientific (US), Danaher Corporation (US), and Bio-Rad Laboratories (US). In 2021, Abbott (US held the leading position in the market. The company has a strong geographic presence across North America, Europe, and Asia Pacific. Thermo Fisher Scientific (US) held the second position in the therapeutic drug monitoring market in 2021.

Therapeutic Drug Monitoring Market Report Scope

Report Metric

Details

Market Revenue in 2022

$1.8 billion

Estimated Value by 2027

$2.9 billion

Growth Rate

Poised to grow at a CAGR of 9.6%

Forecast Units

Value (USD)

Segments Covered

Product, Technology, Class of drugs, End User and Region

Geographies Covered

North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World (Latin America- and Middle East & Africa)

Companies Covered

Abbott (US)
Thermo Fisher Scientific (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Siemens Healthineers AG (Germany)
Danaher Corporation (US)
Bio-Rad Laboratories (US), Among others.

This research report categorizes the Therapeutic Drug Monitoring market into the following segments and subsegments:

Product Split

Technology Split

  • Immunoassays.
  • Chemiluminescence Immunoassays
  • Chemiluminescence Immunoassays
  • Colorimetric Immunoassays
  • Fluorescence Immunoassays
  • Radioimmunoassay
  • Other Immunoassays
  • Chromatography-MS
  • LC-MS
  • GC-MS

Class of drug Split

  • Antiepileptic Drugs
  • Antibiotic Drugs
  • Immunosuppressant Drugs
  • Antiarrhythmic Drugs
  • Bronchodilator Drugs
  • Psychoactive Drugs
  • Other Drugs

End user Split

  • Hospital Laboratories
  • Commercial & Private Laboratories
  • Other End Users

Recent Developments:

  • In May 2012, Theradiag (France) announced the launch of ez-Track1, a point-of-care testing solution for therapeutic drug monitoring.
  • In January 2021, Theradiag (France) announced CE marking for four new i-Tracker test kits for biotherapy monitoring.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 28)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 GEOGRAPHIC SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    TABLE 1 KEY DATA FROM PRIMARY SOURCES
                    FIGURE 3 KEY INDUSTRY INSIGHTS
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                    FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    FIGURE 7 APPROACH 3: MARKET SIZE ESTIMATION FROM PARENT MARKET
                    2.2.1.1 Growth forecast
                                FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                                FIGURE 9 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
    2.7 IMPACT OF RECESSION 
 
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 GEOGRAPHIC ANALYSIS: THERAPEUTIC DRUG MONITORING MARKET
 
4 PREMIUM INSIGHTS (Page No. - 49)
    4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW 
          FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE TDM MARKET
    4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY AND DRUG CLASS 
          FIGURE 17 ANTIEPILEPTIC DRUGS ACCOUNTED FOR LARGEST SHARE IN 2021
    4.3 THERAPEUTIC DRUG MONITORING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 CHINA TO REGISTER HIGHEST CAGR
    4.4 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (2022–2027) 
          FIGURE 19 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.5 THERAPEUTIC DRUG MONITORING MARKET: DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Importance of TDM in organ transplant procedures
                                FIGURE 22 UK: NUMBER OF DECEASED DONORS AND TRANSPLANTS (APRIL 1, 2017–MARCH 31, 2021)
                    5.2.1.2 Use of TDM across various therapeutic fields
                                TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING
                    5.2.1.3 Increasing preference for precision medicine
                                FIGURE 23 PERSONALIZED MEDICINE APPROVALS BY US FDA, 2015–2021
                    5.2.1.4 Growing focus on R&D related to TDM
                                FIGURE 24 NUMBER OF RESEARCH PUBLICATIONS ON TDM (2015–2021)
                    5.2.1.5 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
                                FIGURE 25 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
                                TABLE 3 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investments
                    5.2.2.2 Reluctance of small hospitals to offer TDM services
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing prevalence of autoimmune diseases
                    5.2.3.2 Significant opportunities in BRICS countries
                                FIGURE 26 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019
           5.2.4 CHALLENGES
                    5.2.4.1 Alternatives to conventional TDM
                    5.2.4.2 Operational barriers faced in conducting TDM tests
                    5.2.4.3 Lack of infrastructure and low awareness in low/middle-income countries
    5.3 TECHNOLOGY ANALYSIS 
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 28 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.6 PORTER’S FIVE FORCES ANALYSIS 
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 INTENSITY OF COMPETITIVE RIVALRY
           5.6.3 BARGAINING POWER OF BUYERS
           5.6.4 BARGAINING POWER OF SUPPLIERS
           5.6.5 THREAT OF SUBSTITUTES
    5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
                    TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
           5.7.2 BUYING CRITERIA
                    FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE END USERS
                    TABLE 5 KEY BUYING CRITERIA FOR TOP THREE END USERS
    5.8 REGULATORY LANDSCAPE 
          TABLE 6 REGULATORY AUTHORITIES GOVERNING TDM MARKET
    5.9 KEY CONFERENCES AND EVENTS IN 2022 AND 2023 
          TABLE 7 LIST OF CONFERENCES AND EVENTS, 2022–2023
    5.10 PATENT ANALYSIS 
           FIGURE 31 PATENT ANALYSIS FOR IMMUNOASSAY ANALYZERS
           FIGURE 32 PATENT ANALYSIS FOR CLINICAL CHEMISTRY ANALYZERS
    5.11 PRICING ANALYSIS 
           TABLE 8 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
           TABLE 9 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING PRODUCTS
    5.12 TRADE ANALYSIS 
           TABLE 10 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)
           TABLE 11 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2021 (USD MILLION)
    5.13 ECOSYSTEM ANALYSIS 
           TABLE 12 ROLE IN ECOSYSTEM
           FIGURE 33 KEY MARKET PLAYERS
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 
           FIGURE 34 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING
 
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT (Page No. - 77)
    6.1 INTRODUCTION 
          TABLE 13 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
    6.2 CONSUMABLES 
           6.2.1 REPEAT PURCHASES AND HIGH USAGE OF CONSUMABLES TO DRIVE MARKET
                    TABLE 14 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
    6.3 EQUIPMENT 
          TABLE 15 DRUGS MONITORED USING ANALYTICAL EQUIPMENT
          TABLE 16 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 17 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
           6.3.1 IMMUNOASSAY ANALYZERS
                    6.3.1.1 High efficiency of immunoassay analyzers to ensure end-user demand
                                TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)
           6.3.2 CHROMATOGRAPHY & MS DETECTORS
                    6.3.2.1 Technological advancements to propel growth
                                TABLE 19 CHROMATOGRAPHY & MS DETECTORS: PRODUCT LAUNCHES, BY COMPANY (2020 TO 2021)
                                TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2020–2027 (USD MILLION)
           6.3.3 CLINICAL CHEMISTRY ANALYZERS
                    6.3.3.1 Automation to raise preference for clinical chemistry analyzers
                                TABLE 21 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2020–2027 (USD MILLION)
 
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY (Page No. - 84)
    7.1 INTRODUCTION 
          TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    7.2 IMMUNOASSAYS 
          TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS
                    7.2.1.1 Rapid detection time and good specificity to support growth
                                TABLE 25 CLIA SYSTEMS OFFERED, BY COMPANY
                                TABLE 26 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAYS
                                TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.2.2 FLUORESCENCE IMMUNOASSAYS
                    7.2.2.1 High operability and better sensitivity of FIAs to drive market growth
                                TABLE 28 LIST OF COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS
                                TABLE 29 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.2.3 COLORIMETRIC IMMUNOASSAYS
                    7.2.3.1 Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment
                                TABLE 30 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.2.4 RADIOIMMUNOASSAYS
                    7.2.4.1 High sensitivity in drug detection applications to support market growth
                                TABLE 31 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS
                                TABLE 32 RADIOIMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.2.5 OTHER IMMUNOASSAYS
                    TABLE 33 OTHER IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
    7.3 CHROMATOGRAPHY-MS 
          TABLE 34 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
           7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
                    7.3.1.1 High accuracy to drive demand for LC-MS
                                TABLE 35 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)
           7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
                    7.3.2.1 Drawbacks of GC-MS to challenge market growth
                                TABLE 36 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2020–2027 (USD MILLION)
 
8 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS (Page No. - 95)
    8.1 INTRODUCTION 
          TABLE 37 THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
    8.2 ANTIEPILEPTIC DRUGS 
           8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH
                    TABLE 38 TDM: LIMITATIONS FACED IN NEW ANTIEPILEPTIC DRUGS
                    TABLE 39 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.3 ANTIARRHYTHMIC DRUGS 
           8.3.1 INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND
                    TABLE 40 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.4 IMMUNOSUPPRESSANT DRUGS 
           8.4.1 RISING IMMUNOSUPPRESSANT DEMAND DRIVEN BY INCREASE IN ORGAN TRANSPLANTATION PROCEDURES
                    FIGURE 35 PATIENTS ON WAITING LIST VS. TRANSPLANTS PERFORMED, BY ORGAN, 2021
                    TABLE 41 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.5 ANTIBIOTIC DRUGS 
           8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND FOR ANTIBIOTIC DRUG MONITORING
                    TABLE 42 COMPARISON OF DIFFERENT TECHNOLOGIES FOR DETERMINING ANTIMICROBIALS LEVELS IN BIOFLUIDS
                    TABLE 43 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.6 BRONCHODILATOR DRUGS 
           8.6.1 RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING
                    TABLE 44 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.7 PSYCHOACTIVE DRUGS 
           8.7.1 SURGING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH
                    TABLE 45 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
    8.8 OTHER DRUGS 
          TABLE 46 OTHER DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
 
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER (Page No. - 104)
    9.1 INTRODUCTION 
          TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 HOSPITAL LABORATORIES 
           9.2.1 HOSPITAL LABS TO DOMINATE END-USER MARKET
                    TABLE 48 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
    9.3 COMMERCIAL & PRIVATE LABORATORIES 
           9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES
                    TABLE 49 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
    9.4 OTHER END USERS 
          TABLE 50 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
 
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (Page No. - 108)
     10.1 INTRODUCTION 
             TABLE 51 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 36 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
                        TABLE 52 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 53 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 54 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 55 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 56 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 57 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 58 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                        TABLE 59 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Awareness regarding precision medicine to propel market
                                      TABLE 60 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS
                                      TABLE 61 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 62 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 63 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 64 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 65 US: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 66 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Availability of funding for research to offer growth opportunities
                                      TABLE 67 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 68 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 69 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 70 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 71 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 72 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 73 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 74 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 75 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 76 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 77 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 78 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 79 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                        TABLE 80 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Prevalence of chronic medical conditions such as cancer and diabetes to support market growth
                                      TABLE 81 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 82 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 83 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 84 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 85 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 86 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.3 ITALY
                        10.3.3.1 Rising incidence of cancer to drive demand for TDM
                                      TABLE 87 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
                                      TABLE 88 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 89 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 90 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 91 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 92 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 93 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Rising awareness of benefits of TDM to accelerate demand
                                      TABLE 94 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 95 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 96 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 97 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 98 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 99 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Adoption of technologically advanced immunoassays to boost market
                                      TABLE 100 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
                                      TABLE 101 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 102 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 103 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 104 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 105 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 106 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.6 UK
                        10.3.6.1 Increasing cases of chronic diseases to support market
                                      TABLE 107 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 108 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 109 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 110 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 111 UK: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 112 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 113 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 114 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 115 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 116 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 117 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                        TABLE 118 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 37 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
                        TABLE 119 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 120 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 121 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 122 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 123 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 124 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY- MS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 125 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                        TABLE 126 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Japan to dominate APAC market
                                      TABLE 127 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
                                      TABLE 128 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 129 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 130 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 131 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 132 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 133 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Rising number of organ transplants to boost market
                                      TABLE 134 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 135 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 136 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 137 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 138 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 139 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Rising incidence of cancer to propel market
                                      TABLE 140 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                                      TABLE 141 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 142 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 143 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 144 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                                      TABLE 145 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.5 ROAPAC
                        TABLE 146 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 147 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 148 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 149 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 150 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                        TABLE 151 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.5 REST OF THE WORLD 
             10.5.1 ROW: RECESSION IMPACT
                        TABLE 152 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
                        TABLE 153 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 154 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 155 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 156 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 157 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS, 2020–2027 (USD MILLION)
                        TABLE 158 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2020–2027 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 158)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 159 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS 
             FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS
     11.4 MARKET SHARE ANALYSIS 
             TABLE 160 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 39 COMPANY EVALUATION QUADRANT: THERAPEUTIC DRUG MONITORING MARKET, 2021
     11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 40 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: THERAPEUTIC DRUG MONITORING MARKET, 2021
     11.7 COMPANY FOOTPRINT ANALYSIS 
             TABLE 161 COMPANY FOOTPRINT
             TABLE 162 COMPANY REGIONAL FOOTPRINT
             TABLE 163 COMPANY PRODUCT FOOTPRINT
     11.8 THERAPEUTIC DRUG MONITORING MARKET: DETAILED LIST OF KEY START-UPS/SMES 
     11.9 COMPETITIVE SCENARIO 
             11.9.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 164 KEY PRODUCT LAUNCHES & APPROVALS
             11.9.2 DEALS
                        TABLE 165 KEY DEALS
             11.9.3 OTHER DEVELOPMENTS
                        TABLE 166 KEY OTHER DEVELOPMENTS
 
12 COMPANY PROFILES (Page No. - 170)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 ABBOTT
                        TABLE 167 ABBOTT: BUSINESS OVERVIEW
                        FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2021)
             12.1.2 THERMO FISHER SCIENTIFIC
                        TABLE 168 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 42 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021)
             12.1.3 F. HOFFMANN-LA ROCHE
                        TABLE 169 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                        FIGURE 43 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
             12.1.4 SIEMENS HEALTHINEERS AG
                        TABLE 170 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
                        FIGURE 44 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             12.1.5 DANAHER CORPORATION
                        TABLE 171 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.6 BIO-RAD LABORATORIES
                        TABLE 172 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 46 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.7 BIOMÉRIEUX SA
                        TABLE 173 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 47 BIOMÉRIEUX: COMPANY SNAPSHOT (2021)
             12.1.8 THERADIAG
                        TABLE 174 THERADIAG: BUSINESS OVERVIEW
                        FIGURE 48 THERADIAG: COMPANY SNAPSHOT (2021)
             12.1.9 GRIFOLS S.A.
                        TABLE 175 GRIFOLS S.A.: BUSINESS OVERVIEW
                        FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
             12.1.10 EXAGEN INC.
                        TABLE 176 EXAGEN INC.: BUSINESS OVERVIEW
                        FIGURE 50 EXAGEN INC.: COMPANY SNAPSHOT (2021)
             12.1.11 ARK DIAGNOSTICS, INC.
                        TABLE 177 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW
             12.1.12 R-BIOPHARM AG
                        TABLE 178 R-BIOPHARM AG: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 APDIA GROUP
             12.2.2 BIOTEZ BERLIN BUCH GMBH
             12.2.3 EAGLE BIOSCIENCES, INC.
             12.2.4 JASEM LABORATORY SYSTEMS AND SOLUTIONS
             12.2.5 AALTO SCIENTIFIC, LTD.
             12.2.6 IMMUNDIAGNOSTIK AG
             12.2.7 UTAK
             12.2.8 SEKISUI MEDICAL CO., LTD.
             12.2.9 DIASYSTEM SCANDINAVIA AB
             12.2.10 CAMBRIDGE LIFE SCIENCES LIMITED
             12.2.11 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH
             12.2.12 BÜHLMANN LABORATORIES AG
             12.2.13 SJK GLOBAL, LLC.
             12.2.14 EPITOPE DIAGNOSTICS, INC.
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 214)
     13.1 INSIGHTS FROM INDUSTRY EXPERTS 
     13.2 DISCUSSION GUIDE 
     13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.4 CUSTOMIZATION OPTIONS 
     13.5 RELATED REPORTS 
     13.6 AUTHOR DETAILS 

The study involved four major activities in estimating the current size of the Therapeutic Drug Monitoring market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (heads of private labs, Diagnostics and hospitals, Scientists, Researchers) and supply sides (Therapeutic Drug Monitoring manufacturers and distributors).

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Therapeutic Drug Monitoring Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2. Tiers of companies are defined based on their total revenue. As of 2020: Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the Therapeutic Drug Monitoring market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Therapeutic Drug Monitoring industry.

Report Objectives

  • To define, describe, and forecast the global Therapeutic Drug Monitoring market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the Therapeutic Drug Monitoring market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
  • Geographic Analysis:  Further breakdown of the European Therapeutic Drug Monitoring market into specific countries.  
Report Code
MD 4185
Published ON
Feb, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Therapeutic Drug Monitoring Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback